AtCor wins $3.2m SphygmoCor deal

AtCor Medical (ASX:ACG) has won a $3.2 million contract to supply its SphygmoCor specialist blood pressure monitoring systems for multiple clinical trial sites.

The deal will see AtCor provide SphygmoCor units and clinical trial support services for sites in Europe and North America.

The name of the buyer was not disclosed, but AtCor CEO Duncan Ross said the pharmaceutical company is an “existing client that we have worked with for a number of years.”

SphygmoCor systems are designed to assess the performance of cardiovascular systems, chiefly central aortic blood pressure. As well as clinical trials, the products are designed for use in cardiovascular risk detection and management.

The size of the contract is particularly large compared to AtCor's typical SphygmoCor deals. The coup follows AtCor's August announcement that it had won a $1.1 million deal covering the supply of new-generation SphygmocCor XCEL units.

Ross said the deals together represent “a very good start to our financial year.”

SphygmoCor XCEL launched in May this year. The company is currently pursuing FDA approval for the new product, and hopes to receive the all-clear by the end of the year.

AtCor Medical (ASX:ACG) shares were trading 1.67% higher at $0.061 as of around 3 pm on Monday.